{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:59:10Z","timestamp":1791568750904,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["LCYSSQ20220823091402005"],"award-info":[{"award-number":["LCYSSQ20220823091402005"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This real-world study evaluated the efficacy and safety of telitacicept, a dual BAFF\/APRIL inhibitor, in patients with generalized myasthenia gravis (MG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, 17 myasthenia gravis patients on stable background therapy received weekly subcutaneous telitacicept (160\u2013240\u202fmg). Efficacy was evaluated at 12\/24\u202fweeks using a primary composite endpoint (\u22652-point MG-ADL and \u22653-point QMG reduction). A pre-specified Bayesian analysis, updating a conservative prior with observed data, was employed to determine the posterior probability of treatment success and its 95% credible interval. Safety and steroid-sparing effects were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 15 patients evaluable for efficacy (\u226512\u202fweeks treatment), 12 (80.0%) met the composite efficacy endpoint. Significant improvements were observed: mean MG-ADL decreased from 8.0\u202f\u00b1\u202f4.4 to 4.2\u202f\u00b1\u202f3.1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01); mean QMG decreased from 13.8\u202f\u00b1\u202f5.5 to 7.6\u202f\u00b1\u202f4.3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). A robust steroid-sparing effect was demonstrated: the mean daily prednisone dose decreased by 76.0% (10.41\u202f\u00b1\u202f7.30\u202fmg to 2.50\u202f\u00b1\u202f3.21\u202fmg,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05), with 3 patients achieving complete withdrawal. Five patients attained Minimal Symptom Expression. Bayesian analysis yielded a posterior mean efficacy rate of 66.67% (95% CrI: 49.99\u201381.43%), with a probability (P) of exceeding 50% efficacy at 97.49%. Treatment was well-tolerated: only mild, transient AEs occurred (one injection-site reaction, one gastrointestinal event leading to withdrawal), and no serious adverse events (SAEs) were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study utilizing Bayesian analysis provides evidence supporting a high probability of efficacy for telitacicept in AChR-Ab-positive MG, demonstrating significant symptom improvement, substantial steroid-sparing effects, and favorable safety. These findings complement prior randomized controlled trial data and support the use of telitacicept in clinical practice. Study limitations include retrospective design and small sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1736049","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:25:42Z","timestamp":1769491542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Telitacicept demonstrates high probability of efficacy in myasthenia gravis: a Bayesian real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinyi","family":"Duan","sequence":"first","affiliation":[{"name":"Shenzhen University Medical School, Shenzhen University","place":["Shenzhen, Guangdong, China"]},{"name":"Department of Neurology, Neuromedicine Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, Guangdong Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Shenzhen University Medical School, Shenzhen University","place":["Shenzhen, Guangdong, China"]},{"name":"Department of Neurology, Neuromedicine Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, Guangdong Province, China"]},{"name":"Shenzhen Clinical Research Center for Rare Diseases","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari","year":"2021","journal-title":"J Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2020","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"596791","DOI":"10.3389\/fneur.2021.596791","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent NMOSD: study protocol for a single-center, single-arm, open-label study","volume":"12","author":"Ding","year":"2021","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e200331","DOI":"10.1212\/NXI.0000000000200331","article-title":"Ravulizumab and Efgartigimod in myasthenia gravis: a real-world study","volume":"12","author":"Stascheit","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1212\/WNL.0000000000211912","article-title":"Management of Myasthenia Gravis around the globe: consensus guidelines versus realities of practice (P1-11.030)","volume":"104","author":"Thawani","year":"2025","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1474-4422(18)30037-1","article-title":"Distinct representation of muscle weakness in QMG and MG-ADL","volume":"17","author":"de Meel","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"17562864241251476","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1164\/rccm.202310-1757VP","article-title":"What is the point of Bayesian analysis?","volume":"209","author":"Goligher","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"20220158","DOI":"10.1098\/rsta.2022.0158","article-title":"Bayesian approaches to include real-world data in clinical studies","volume":"381","author":"M\u00fcller","year":"2023","journal-title":"Philos Trans R Soc A Math Phys Eng Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis","volume":"38","author":"Ma","year":"2024","journal-title":"CNS Drugs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jama.2017.15574","article-title":"Bayesian analysis: using prior information to interpret the results of clinical trials","volume":"318","author":"Quintana","year":"2017","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of Bayesian approaches in drug development: starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-022-02342-5","article-title":"Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles","volume":"17","author":"Kidwell","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2165\/00003495-200565070-00005","article-title":"Tacrolimus: in patients with rheumatoid arthritis","volume":"65","author":"Curran","year":"2005","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/acn3.51746","article-title":"Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis","volume":"10","author":"Fan","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.it.2017.02.001","article-title":"Expanding the B cell-centric view of systemic lupus erythematosus","volume":"38","author":"Morawski","year":"2017","journal-title":"Trends Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","volume":"39","author":"Bergantini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/neurolint17100163","article-title":"Management of Myasthenic Crisis and Emerging Roles of molecularly targeted therapies: a narrative review","volume":"17","author":"Takahashi","year":"2025","journal-title":"Neurol Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e50692","DOI":"10.7759\/cureus.50692","article-title":"Exacerbation of Thymoma-associated myasthenia gravis following Efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: a report of two cases","volume":"15","author":"Kawama","year":"2023","journal-title":"Cureus"},{"key":"ref37","first-page":"1171","article-title":"Retrospective studies and chart reviews","volume":"49","author":"Hess","year":"2004","journal-title":"Respir Care"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1736049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:12:46Z","timestamp":1771924366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1736049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":37,"alternative-id":["10.3389\/fneur.2025.1736049"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1736049","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1736049"}}